Skip to content

pH-sensitive polymer-drug conjugate: An approach to evaluate the effect of the linker on doxorubicin release.

Aug 2026 · Journal of Pharmacy and Science · pp. 104481 · 0 citations · 51 references
Medicine

TL;DR

Two pH-sensitive F127-Dox conjugates were synthesized using cis-aconitic (Cis) and succinic (Suc) linkers and demonstrates superior pH-responsiveness and drug-loading capacity, making it a promising candidate for tumor-targeted doxorubicin delivery.

Abstract

Conventional chemotherapy with doxorubicin (Dox) is limited by poor selectivity and systemic toxicity. Polymeric micelles based on Pluronic F127 offer a versatile platform for drug delivery, but their stability and responsiveness to tumor-specific stimuli remain critical challenges. To address these issues, two pH-sensitive F127-Dox conjugates were synthesized using cis-aconitic (Cis) and succinic (Suc) linkers. The conjugates were structurally characterized by FTIR and 1H NMR, and their micellization behavior was studied via pyrene fluorescence. Dynamic light scattering was employed to analyze micelle size and pH responsiveness, while UV-Vis spectrophotometry was used to quantify drug loading (DL%) and encapsulation efficiency (EE%). Drug release kinetics were evaluated using the dialysis method at pH 7.4 and 5.5. Conjugation reduced the CMC of F127 from 112 μg/mL to 89 μg/mL (Cis-Dox) and 75 μg/mL (Suc-Dox), enhancing micellar stability. F127-Cis-Dox achieved higher drug loading (5.54%) and encapsulation efficiency (61.8%) compared to F127-Suc-Dox (3.42%, 37.0%) and physically loaded F127-Dox micelles (4.94%, 60.3%). In vitro release showed pronounced pH sensitivity: F127-Cis-Dox released 80.7% of Dox at pH 5.5, compared with 25.2% at pH 7.4, whereas F127-Suc-Dox released 65.0% versus 33.9%, respectively. By contrast, F127-Dox exhibited rapid, nonspecific release (∼85% at pH 7.4, 144 h). These results highlight the importance of linker chemistry in tuning micelle stability and drug release. F127-Cis-Dox, in particular, demonstrates superior pH-responsiveness and drug-loading capacity, making it a promising candidate for tumor-targeted doxorubicin delivery.

View source

Similar papers

Open access Jun 2026

Folic acid-targeted polymeric complex imprinted with doxorubicin and quercetin for controlled drug delivery in cancer therapy

This study demonstrates the structural feasibility of a folic acid-functionalized imprinted polymer system capable of controlled release under acidic conditions, presenting a material-level physicochemical evaluation of a dual-drug imprinted polymeric platform.

Ceren Türkcan, Emirhan Işeri · 0 citations
Sep 2026

Co-loaded pH-Responsive AOT Nanovesicles for Combinatorial Chemotherapy: Structure, Stability, and Mechanism of Drug Release and Anti-Cancer Activity

The development of biocompatible sodium bis(2-ethylhexyl) sulfosuccinate (AOT)-based nanovesicles for the co-delivery of hydrophilic and hydrophobic anti-cancer agents, doxorubicin and curcumin are reported.

Khushnuma Asghar, Kumari Kiran, Bharath Raj Parthasarathy et al. · 0 citations
Open access Sep 2026

Development and Evaluation of PEGylated Polymer Functionalized Magnetic Nanoparticles for Controlled Delivery of Sunitinib Malate: Study of Drug Release Kinetic

Sunitinib malate (STB) is an effective multi‐target tyrosine kinase inhibitor used against several cancers, but its use is limited by non‐specific distribution, low bioavailability, and poor water solubility. This study explores nanocarrier‐based delivery systems to improve STB's therapeutic efficiency. Specificall...

Mina Norouzmoghadamabkenar, Amir Heydarinasab, Homayon Ahmad Panahi et al. · 0 citations
Sep 2026

Engineering Poly(ε-caprolactone)-Based Maleimide−Enediyne Micelles for Next-Generation Anticancer Therapies

Cell viability assays showed enediyne-induced death in MDA-MB-231 breast cancer cells, and the functionalized PCL exhibited in vitro DNA cleaving activity, demonstrating that maleimide−enediyne-functionalized PCL micelles are promising platforms for cancer chemotherapy.

Abhi Bhadran, G. Babanyinah, Himanshu Polara et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.